Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background & Aims: Lymphocyte-rich hepatocellular carcinoma (LR-HCC) is largely unknown and a rare subtype of HCC with immune-rich stroma. Tertiary lymphoid structures (TLS), frequently observed in LR-HCC, are known to be prognostically significant in various malignancies; however, their significance in HCC remains unevaluated.
Methods: Clinicopathologic data of 191 cases of surgically resected conventional HCC (C-HCC, n = 160) and LR-HCC (n = 31) were retrieved. Immunohistochemistry, multiplex immunofluorescence staining, RNA sequencing and proteomic analysis were conducted. Differences between the subtypes were statistically evaluated.
Results: LR-HCC was significantly correlated to larger tumour size, higher Edmondson-Steiner grade, presence of TLS and higher CD3-, CD8- and FOXP3-positive T cell, high PD-1 and PD-L1 expression (p < .001 for all) compared to C-HCC. Patients with LR-HCC exhibited significantly better overall survival (OS) (p = .044) and recurrence-free survival (RFS) (p = .025) than C-HCC. LR-HCC demonstrated TLS signatures with significantly higher proteomic-based immune scores in 14 of 17 types of tumour-infiltrating immune cells. Furthermore, C-HCC with secondary follicles, the most mature form of TLS, exhibited significantly better OS (p = .031) and RFS (p = .033) than those without. Across the global proteome, LR-HCC was well-differentiated from C-HCC and a map of protein-protein interactions between tumour-infiltrating lymphocytes and HCC in tumour microenvironment was completed.
Conclusion: LR-HCC is clinicopathologically and molecularly distinct and shows better prognosis compared to C-HCC. Also, the presence of secondary follicle can be an important prognostic marker for better prognosis in both LR-HCC and C-HCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/liv.15865 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The histopathological and molecular heterogeneity of hepatocellular carcinoma: a narrative review.
Ewha Med J
October 2024
Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related deaths worldwide, with poor clinical outcomes due to challenges in early detection and limited efficacy of current treatments such as receptor tyrosine kinase inhibitors and immunotherapy. HCC exhibits significant heterogeneity at both histopathological and molecular levels, complicating its management but offering potential for personalized therapeutic approaches. This review outlines the morpho-molecular heterogeneity of HCC and summarizes various histological subtypes, including steatohepatitic, clear cell, macrotrabecular-massive, scirrhous, lymphocyte-rich, and fibrolamellar HCCs.
View Article and Find Full Text PDFBovine hepatocellular carcinoma histomorphologically and comparative pathologically analogous to human lymphocyte-rich hepatocellular carcinoma.
J Comp Pathol
July 2025
Department of Histopathology, Diagnostic Animal Pathology Office, Nishino 11-9/20-25, Sapporo, 063-0041, Hokkaido, Japan. Electronic address:
Human lymphocyte-rich hepatocellular carcinoma (LrHCC), a very rare HCC subtype associated with a favourable prognosis, has been debated on its existence as a distinct entity. Although HCC has been reported in all species of domestic animals, primary hepatic neoplasia similar to or identical with LrHCC has not been reported in cattle. Necropsy of an 8-year-old Holstein-Friesian slaughtered dairy cow revealed the presence of a hepatic neoplasm that was verified histopathologically as very similar to LrHCC on the basis of histomorphological and comparative pathological features.
View Article and Find Full Text PDFHepatocellular carcinoma: Morphological spectrum and subtyping as per the World Health Organization classification on FNA biopsy with cell block samples.
Cancer Cytopathol
April 2025
Department of Cytology and Gynaecological Pathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Background: Hepatocellular carcinoma (HCC) may be diagnosed and further subclassified in surgical specimen as per the recent World Health Organization (WHO) classification into several distinct subtypes with prognostic implications. The aim of this study was to apply this WHO classification on fine-needle aspiration biopsy (FNAB) samples of HCC and describe their features.
Methods: This was a retrospective analysis of all ultrasound-guided FNAB of liver mass lesions in patients with suspected HCC (n = 164) over a 7-year period.
[Hepatocellular carcinoma: Histological and molecular classifications].
Ann Pathol
May 2025
Université Paris Cité, Paris, France; Département de pathologie, FHU MOSAIC, SIRIC InSitu, hôpital Beaujon, AP-HP. Nord, Clichy, France; Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
Article Synopsis
- Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a poor prognosis, contributing significantly to cancer-related deaths globally.
- The tumor exhibits both morphological and molecular diversity, with the World Health Organization identifying eight subtypes based on histological characteristics, including steatohepatitic and macrotrabecular massive (MTM), some of which are linked to worse survival rates.
- Genomic analysis shows common mutations like TERT, as well as later mutations in TP53 and CTNNB1, with TP53 mutations correlating to poorer outcomes, emphasizing the need for detailed subtype classification for better prognosis assessments.
Clinicopathologic features and tumor immune microenvironment of lymphocyte-rich hepatocellular carcinoma.
Ann Diagn Pathol
December 2024
Department of Pathology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province 510630, China. Electronic address:
Lymphocyte-rich hepatocellular carcinoma (LR-HCC) is a rare variant of HCC characterized by pronounced lymphoid infiltration, providing an opportunity to explore the tumor immune microenvironment (TIME) and its potential impact on disease progression and therapy. This study aimed to describe the clinicopathological features and TIME components of LR-HCC to inform more effective treatment strategies. In this study, we present five novel cases of LR-HCC alongside a comprehensive retrospective analysis of 136 previously documented cases.
View Article and Find Full Text PDF